Milei Threatens Falkland Oil Firms With Sanctions 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
EMERYVILLE, Calif., Feb. 27, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.
| Conference Call Details | |||||||
| Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |||||||
| Toll Free: | 800-239-9838 | ||||||
| International: | 323-794-2551 | ||||||
| Conference ID: | 5092266 | ||||||
| Webcast: | http://public.viavid.com/index.php?id=128365 | ||||||
| Replays, available through March 20: | |||||||
| Domestic: | 844-512-2921 | ||||||
| International: | 412-317-6671 | ||||||
| Replay PIN: | 5092266 | ||||||
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
